Compare Eli Lilly And Co (LLY) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs NEOS S&P 500 High Income ETF — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while NEOS S&P 500 High Income ETF trades at $54.09 (market cap $12.50B). The key difference: Eli Lilly And Co is far larger — about 83.2× NEOS S&P 500 High Income ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while NEOS S&P 500 High Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and NEOS S&P 500 High Income ETF for 58 Days on average.
| LLY | SPYI | |
|---|---|---|
Market Cap | $1.04T | $12.50B |
Volume | 3,064,878 | 3,058,962 |
Sector | Health | Income / Options Overlay |
52-Week High | $1.28K | $54.42 |
52-Week Low | $799.57 | $47.98 |
Typical Hold Time | 93 Days | 58 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
SPYI trades at $53.86, down 0.28% with a bullish technical signal from moving averages but neutral oscillators. The ETF shows strong income focus with recent monthly dividends around $0.53-0.54, though financial ratios remain undisclosed. Recent news highlights SPYI's popularity for high-yield strategies while raising concerns about principal erosion from covered call strategies.
Outlook remains mixed with technical strength offset by fundamental questions about long-term capital preservation. The ETF appeals to income-seeking investors but faces sequence risk in retirement portfolios. Key risks include covered call limitations during bull markets and sensitivity to market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
